Rifampin

Tuberculosis

Volumn 88, Issue 2, 2008, Pages 151-154

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ABRIFAM; ASTEMIZOLE; CARBAMAZEPINE; CORTICOSTEROID; CYCLOSPORIN; DAPSONE; DRUG DERIVATIVE; INDINAVIR; ISONIAZID; KETOCONAZOLE; METHADONE; PARACETAMOL; PHENOBARBITAL; PHENYTOIN; PYRAZINAMIDE; QUINIDINE; RIFABUTIN; RIFALAZIL; RIFAMPICIN; RIFAPENTINE; RIFAPIAM; RIFAPRODIN; TERFENADINE; THEOPHYLLINE; VERAPAMIL; WARFARIN;

AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC RESISTANCE; BILE ACID BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BIOLOGY; CHEMOTHERAPY INDUCED EMESIS; CHRONIC TOXICITY; CLINICAL TRIAL; DIARRHEA; DRUG DOSE INCREASE; DRUG POTENCY; DRUG SAFETY; DRUG SOLUBILITY; DYSPNEA; HEMOLYTIC ANEMIA; HUMAN; HYPOTENSION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FAILURE; LIVER FUNCTION TEST; LIVER TOXICITY; MYCOBACTERIUM TUBERCULOSIS; NAUSEA; NONHUMAN; OPTIMAL DRUG DOSE; ORGANIC BRAIN SYNDROME; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; SHOCK; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TUBERCULOSIS;

ANIMALS; ANTIBIOTICS, ANTITUBERCULAR; HUMANS; RIFAMPIN; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 43249128574     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-9792(08)70024-6     Document Type: Review

References (26)

1. Vernon A. Rifamycin antibiotics, with a focus on newer agents. In: Rom W., and Garay S. (Eds). Tuberculosis. 2nd edition (2003), Lippincott Williams & Wilkins, Philadelphia, PA 759-771
2. Wehrli W., et al. Interaction of rifamycin with bacterial RNA polymerase. Proc Natl Acad Sci 61 (1968) 667-673
3. Engelburg-Kulka H., et al. Bacterial programmed cell death systems as targets for antibiotics. Trends Microbiol 12 (2004) 66-70
4. Huitric E., et al. Resistance levels and rpoB gene mutations among in vitro-selected rifampin-resistant Mycobacterium tuberculosis mutants. Antimicrob Agents Chemother 50 (2006) 2860-2862
5. Xu M., et al. Cross-resistance of Escherichia coli RNA polymerases conferring rifampin resistance to different antibiotics. J Bacteriol 187 (2005) 2783-2792
6. Willams D., et al. Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobac-terium tuberculosis. Antimicrob Agents Chemother 42 (1998) 1853-1857
7. Mitchison D. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis 4 (2000) 796-806
8. Rastogi N., et al. In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages. Curr Microbiol 33 (1996) 167-175
9. Sasaki H., et al. Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles. J Med Chem 49 (2006) 7854-7860
10. Reddy V., et al. Antimycobacterial activity of a new rifamycin derivative, 3-(4-cinnamylpiperazinyl iminomethyl) rifamycin SV (T9). Antimicrob Agents Chemother 39 (1995) 2320-2324
11. Bemer-Melchior P., et al. Comparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis complex. J Antimicrob Chemother 46 (2000) 571-576
12. Jayaram R., et al. Pharmacokinetics pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 47 (2003) 2118-2124
13. Bhusal Y., et al. Determination of in vitro synergy when three antimicrobial agents are combined against Mycobacterium tuberculosis. Int J Antimicrob Agents 26 (2005) 292-297
14. Rastogi N., et al. In vitro activities of levofloxacin used alone and in combination with first-and second-line antituberculous drugs against Mycobacterium tuberculosis. Antimicrob Agents Chemother 40 (1996) 1610-1616
15. Grosset J., and Ji B. Experimental chemotherapy of mycobacterial diseases. In: Gangadharan P., and Jenkins P. (Eds). Mycobacteria: II. Chemotherapy (1998), Chapman and Hall 51-96
16. Pandey R., et al. Poly (dl-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother 52 (2003) 981-986
17. Pandey R., et al. Liposome-based antitubercular drug therapy in a guinea pig model of tuberculosis. Int J Antimicrob Agents 23 (2004) 414-415
18. Burman W., et al. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet 40 (2001) 327-341
19. Labana S., et al. Chemotherapeutic activity against murine tuberculosis of once weekly administered drugs (isoniazid and rifampicin) encapsulated in liposomes. Int J Antimicrob Agents 20 (2002) 301-304
20. Doel P., et al. Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice. Antimicrob Agents Chemother 41 (1997) 1211-1224
21. Karthikeyan S. Isoniazid and rifampicin treatment on phospholipids and their subfractions in liver tissue of rabbits. Drug Chem Tox 28 (2005) 273-280
22. www.inchem.org/
23. Douglas J., and McLeod M. Pharmacokinetic factors in the modern drug treatment of tuberculosis. Clin Pharmacokinet 37 (1999) 127-146
24. Back D., et al. Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS 16 Suppl (2002) S5-37
25. Yew W. Clinically significant interactions with drugs used in the treatment of tuberculosis. Drug Saf 25 (2002) 111-133
26. Schaberg T., et al. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir Rev 4 (1995) 1247-1249